TOP 100 MEDICAL SITES
| |||
|
| |||
| |||
|
| |||
| Pig-Virus DNA Found In Merck Vaccine The FDA said fragments of two types of pig viruses were found in Merck's Rotateq vaccine. online.wsj.com |
Medicare to Weigh Coverage for Dendreon Drug The U.S. government said it would analyze whether covering the costs of Provenge, Dendreon's expensive immunotherapy treatment for prostate cancer, is "reasonable and necessary." online.wsj.com |
The Do-It-Yourself House Call Insurer-endorsed remote-monitoring technology leads heart patients to take their own readings at home. online.wsj.com |
The Upcoming Verdict on Arena's Obesity Drug Prohost Biotech submits:This Thursday an FDA advisory panel will discuss Arena’s (ARNA) drug Lorqess (lorcaserin) for obesity. The stock has already been cremated, losing more than 30% of its value because the Food and Drug Administration posted what insinuates that, on the one hand, clinical studies of lorcaserin showed the product did not meet the standard FDA guidance for industry developing products for weight management, i.e., that the difference in mean weight loss between the active-product and placebo-treated groups must be at least 5% for a statistically significant difference between the drug to be reviewed and the placebo. In this study, the average weight loss with lorcaserin was about 3% greater than the average weight loss for patients given a placebo. On the other hand, the FDA said a product is considered effective if it meets at least one of the criteria after one year of treatment, which Arena’s drug might have met. The agency said that about 23% of patients in the placebo group lost 5% or more of their body weight after one year compared to 47% of people being given lorcaserin twice a day. The results were 40% of people who took the drug once daily. This statement did not reach the eyes or ears of investors who were affected by fear more than by encouragement. Complete Story » seekingalpha.com |
Trius to Present at 7th Anti-Infectives Partnering and Deal-Making Summit [PR Newswire] - Trius Therapeutics, Inc. announced today that Karen Joy Shaw, Ph.D., Senior Vice President of Biology at Trius Therapeutics, will present at the 7th Anti-Infectives Partnering and Deal-making Summit taking place in Boston October 7-8, 2010. Â The presentation, titled "Torezolid: The Second Generation," will take place at 10:50 a.m. us.rd.yahoo.com |